CN1296069C - Preparing technics of composition of Guizhi and Fuling and its use - Google Patents
Preparing technics of composition of Guizhi and Fuling and its use Download PDFInfo
- Publication number
- CN1296069C CN1296069C CN 200310116836 CN200310116836A CN1296069C CN 1296069 C CN1296069 C CN 1296069C CN 200310116836 CN200310116836 CN 200310116836 CN 200310116836 A CN200310116836 A CN 200310116836A CN 1296069 C CN1296069 C CN 1296069C
- Authority
- CN
- China
- Prior art keywords
- poria
- extract
- hour
- crude drug
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 101
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000000284 extract Substances 0.000 claims abstract description 69
- 239000000843 powder Substances 0.000 claims abstract description 51
- 238000000605 extraction Methods 0.000 claims abstract description 43
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 47
- 238000010992 reflux Methods 0.000 claims description 40
- 239000000706 filtrate Substances 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 25
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- -1 and oven dry Substances 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 11
- 241000238370 Sepia Species 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 abstract description 68
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 abstract description 34
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 abstract description 34
- 238000005516 engineering process Methods 0.000 abstract description 24
- 210000002307 prostate Anatomy 0.000 abstract description 19
- 244000248825 Peltandra virginica Species 0.000 abstract description 11
- 235000001188 Peltandra virginica Nutrition 0.000 abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 abstract description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 10
- 210000005075 mammary gland Anatomy 0.000 abstract description 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 9
- 206010020718 hyperplasia Diseases 0.000 abstract description 6
- 238000003809 water extraction Methods 0.000 abstract description 2
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 239000008956 guizhi-fuling Substances 0.000 description 90
- 241000700159 Rattus Species 0.000 description 40
- 238000002425 crystallisation Methods 0.000 description 28
- 230000008025 crystallization Effects 0.000 description 28
- 210000004907 gland Anatomy 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 24
- 239000012567 medical material Substances 0.000 description 22
- 230000037396 body weight Effects 0.000 description 20
- 238000010171 animal model Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 238000004321 preservation Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 13
- 230000000762 glandular Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 8
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 8
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229940117916 cinnamic aldehyde Drugs 0.000 description 8
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000001256 steam distillation Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010018691 Granuloma Diseases 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 235000019219 chocolate Nutrition 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 4
- 229960002327 chloral hydrate Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 3
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 239000013521 mastic Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001625 seminal vesicle Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 201000010653 vesiculitis Diseases 0.000 description 3
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000012503 pharmacopoeial method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Abstract
The present invention discloses new preparation technology for a cassia twig and tuckahoe composition. Moreover, the present invention provides the application of the cassia twig and tuckahoe composition in medicine for treating the hyperplasia of prostate glands and the hyperplasia of mammary glands. The preparation technology of the present invention comprises two kinds of preparation technology: in one kind of the preparation technology tree peony bark is singly extracted, and a preferable ratio of the extract amount of tuckahoe to the amount of fine powder is 10% to 30%: 70% to 90%; the other kind of preparation technology adopts a method of combining multiple alcohol extraction with water extraction. The preparation technology is stable and feasible. The content of paeonol of a finished product is higher than that of former technology.
Description
Technical field
The present invention relates to preparation technology of a kind of Chinese medicine composition and uses thereof, particularly relate to preparation technology of a kind of Cinnamomi and poria composition and uses thereof.
Background technology
Ramulus Cinnamomi Poria pill comes from Zhang Zhongjing " Medical Treasures of the Golden Chamber ", it is tcm clinical practice tradition commonly used name side, by Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, Radix Paeoniae 5 flavor medicines are formed, and are modern commonly used for big honeyed pills, are recorded in " Drug Standard of Ministry of Public Health of the Peoples Republic of China Chinese traditional patent formulation preparation " first, has activating blood circulation to dissipate blood stasis, the function of slow detumescence piece.The improvement dosage form of existing Ramulus Cinnamomi Poria pill, its preparation technology lose more in the concentration process of raw material, and spissated extractum density is unfavorable for mixing, and is difficult for drying, take a lot of work, time-consuming, and the extraction ratio of utilization ratio of raw materials, active ingredient is not high.
Summary of the invention
The preparation technology that provides a kind of Cinnamomi and poria composition new is provided the object of the invention.Another purpose of the present invention is to provide the application of Cinnamomi and poria composition in the medicine of treatment prostatic hyperplasia and cyclomastopathy.
The present invention seeks to be achieved through the following technical solutions:
Concrete processing step is as follows: the extracting method of Cortex Moutan should be medical material and breaks into coarse powder 2mm-1cm and add water, and after moistening 1-2 hour, the circulation vapor distillation extracts, and collects 4-10 and doubly measures distillate, and cold preservation is left standstill; After waiting to separate out crystallization, filter, filtrate is redistillation again, collects the distillate that 2.5-3.5 doubly measures, and cold preservation is left standstill; After waiting to separate out crystallization, filter, filtrate discards, and merges twice paeonol crystallization; Be ground into fine powder after drying in the shade, make fine grained, dry in the shade, the cryogenic seal storage, stand-by; The Poria powder of Ramulus Cinnamomi, the Radix Paeoniae Alba, Semen Persicae and recipe quantity 10%-30% is broken into coarse powder, mixing; Add the Cortex Moutan medicinal residues, add 90% ethanol that medical material 3-5 doubly measures again, soaked 0.5-1 hour, heating and refluxing extraction 1-3 hour, filter; Medicinal residues add 90% ethanol that crude drug 3-5 doubly measures again, reflux, extract, 1-3 hour, filter merging filtrate; Medicinal residues add the water that crude drug 5-7 doubly measures, and reflux, extract, 0.5-1 hour, filter; Medicinal residues add the water that crude drug 3-5 doubly measures again, reflux, extract, 0.5-1 hour, filter; Merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia thickness mastic, relative density is 1.25 at 80 ℃; Other 70%-90% recipe quantity is crossed the Poria fine powder and the above-mentioned extractum mixing of 100 mesh sieves, and drying is pulverized, oven dry; Add the paeonol fine grained, mixing, granulate incapsulates, promptly.
The preparation technology of Cinnamomi and poria composition of the present invention can also be following steps:
The Poria five kinds of Chinese medicine of getting Ramulus Cinnamomi, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan and 40%-60% recipe quantity is broken into coarse powder, mixing; Add 70%-90% ethanol, soaked 0.5-1 hour, heating and refluxing extraction 1-3 time wherein adds the alcoholic acid amount of 70%-90% at every turn and is 3-5 times of crude drug, and the heating and refluxing extraction time is 1-3 hour; Filter merging filtrate; Medicinal residues add the water that crude drug 5-7 doubly measures, reflux, extract, 1-3 time, wherein each reflux extracting time 0.5-1 hour; Filter, merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia extractum; With the Poria fine powder and the above-mentioned extractum mixing of other 40%-60% recipe quantity, drying is pulverized, and granulates, and granulate incapsulates, promptly.
Two kinds of its process stabilizings of new preparation technology, feasible of Cinnamomi and poria composition of the present invention, the paeonol content of finished product, cinnamic aldehyde content, content of paeoniflorin are all than former technology height, improve the extraction ratio of utilization ratio of raw materials, active ingredient, its Cinnamomi and poria composition can be used for treating prostatic hyperplasia and hyperplasia of mammary glands.
Following experimental example is used to further specify the present invention.
Extract the comparison of paeonol under experimental example 1 different condition
1 experimental technique: paeonol is slightly soluble in water, can separate out in distillate again during cooling with vapor distillation, simultaneously in conjunction with relevant document, has at first investigated the yield of paeonol under following three kinds of conditions, compares.
Method one, Cortex Moutan medical material 120g added water-wet after 1 hour, adopted circulation steam distillation, collected 9 times of amount distillates, and cold preservation is left standstill, after waiting to separate out crystallization, filter, filtrate is redistillation again, collects 3 times of amount distillates, cold preservation is left standstill, and filters after waiting to separate out crystallization, merges twice crystallization, is designated as A.
Method two, Cortex Moutan medical material 120g add water-wet, add 5%NaCL again, after 1 hour, adopt circulation steam distillation, collect 9 times of amount distillates, cold preservation is left standstill, and after waiting to separate out crystallization, filters, the NaCL that filtrate adds above-mentioned amount is redistillation again, collect 3 times of amount distillates, cold preservation is left standstill, and filters after waiting to separate out crystallization, merge twice crystallization, be designated as B.
Method three, Cortex Moutan medical material 120g add water-wet, add 10%NaCL again, after 1 hour, adopt circulation steam distillation, collect 9 times of amount distillates, cold preservation is left standstill, and after waiting to separate out crystallization, filters, the NaCL that filtrate adds above-mentioned amount is redistillation again, collect 3 times of amount distillates, cold preservation is left standstill, and filters after waiting to separate out crystallization, merge twice crystallization, be designated as C.
After A, B, the crystallization of C paeonol are dried in the shade, put in the exsiccator and spend the night, weigh, get in right amount by " one one 137 pages Cortex Moutan assay items of Chinese pharmacopoeia version in 2000 are operation down, result such as table 1.
Table 1 Cortex Moutan medicinal material extract adds and no salt added comparison
| Project | Paeonol crystallization weight | Sampling amount | Trap | Paeonol content | The paeonol total amount | The paeonol extraction ratio |
| Crystalline A B C | g 1.4858 1.4207 1.3818 | g 0.00670 0.00530 0.00525 | A 0.990 0.815 0.839 | ％ 85.7％ 89.2％ 92.7％ | g 1.2733 1.2673 1.2809 | ％ 62.1 61.8 62.4 |
(it is 1.71% that medical material is surveyed paeonol content by the pharmacopeia method)
2 experimental results: above three kinds of extracting method, the paeonol of crystallization C is purer, but three kinds of extracting method are more or less the same for the paeonol extraction ratio, consider the production actual cost, and employing method one is extracted.Be that the Cortex Moutan medical material is directly used the circulation steam extraction, need be with salt.
The influence that experimental example 2 different factors are extracted for paeonol
1 selectes empirical factor and chooses level: for the other factors that influences the Cortex Moutan medicinal material extract, the present invention has selected " medical material particle diameter ", " wetting time " and factors such as " collecting the amount of distillate ", in conjunction with producing, each factor has been chosen 3 levels again, sees Table 2 simultaneously.
Table 2 factor level table
2 experimental techniques
By the requirement of experimental design scheme, adopt L
9(3
4) experimentize, be that index is passed judgment on the total amount of paeonol, the results are shown in Table 3.
Table 3: orthogonal experiments table
Annotate: 1. the Cortex Moutan medical material detects, and paeonol content is 1.71%.
2. this experiment is an experimental subject with 1/2 recipe quantity Cortex Moutan medical material.
3. the content detection of paeonol method is by " pertinent regulations operation under one one 137 pages Cortex Moutan assay items of Chinese pharmacopoeia version in 2000.
3 experimental results
Table 4 paeonol extraction and application rate analysis of variance table
| Soruces of variation | Sum of deviation square | Degree of freedom | Average variance | The F value | The P value |
| SA SB SC SD | 0.0137 0.0015 0.0231 0.0002 | 2 2 2 2 | 0.0069 0.0008 0.0116 0.0001 | 69 8 116 1.00 | Remarkable significantly especially |
F
0.10(2，2)＝9 F
0.05(2，2)＝19
The A factor has significant difference (P＜0.05) as shown in Table 4, and the C factor has special significant difference (P＜0.01); As shown in Table 3, A
1＜A
2＜A
3, B
3＜B
1＜B
2, C
1＜C
2＜C
3So, should select A
3B
2C
3, but C
2, C
3Be more or less the same, consider production cost, the present invention selects C for use
2Be that the extraction process of Cortex Moutan should be medical material and breaks into coarse powder and cross 10 mesh sieves, add water-wet after 1.5 hours,, collect 7 times of amount distillates with circulation steam distillation, cold preservation is left standstill, after waiting to separate out crystallization, filter, filtrate is redistillation again, collect 3 times of amount distillates, cold preservation is left standstill, and filters after waiting to separate out crystallization, merges twice crystallization by being proposed the paeonol crystallization.
The research that experimental example 3 distillates are accepted or rejected
Break into coarse powder according to the Cortex Moutan medical material and cross 10 mesh sieves, add 1.5 hours Cortex Moutan extraction processes of water-wet, get 2 parts of the Cortex Moutan medical materials of 1/2 recipe quantity, verify, respectively 1. 2. 1.5309g of 1.5248g of paeonol crystallization; Get for the first time raffinate behind the filtrate redistillation, filtrate is made full wavelength scanner respectively for the second time, the collection of illustrative plates peak shape is consistent with the paeonol reference substance.
Experimental example 4 alcohol extractions and extraction process by water are preferred
Getting Ramulus Cinnamomi 240g, Poria 120g, Semen Persicae 240g, Radix Paeoniae Alba 240g, Cortex Moutan 240g, adopt single factor to investigate method, is index with content of effective in the extract, and the alcohol extraction and the extraction process by water of five tastes medical material carried out preferably.
1 five tastes medical material alcohol extraction process is preferred
Contain in the Ramulus Cinnamomi in cinnamic aldehyde, the Cortex Moutan and contain paeonol, the two is all fat-soluble effective ingredient.According to the physicochemical property of material, we are the investigation factor with concentration of alcohol, extraction time, are performance assessment criteria with the content of cinnamic aldehyde and paeonol in the five tastes medical material ethanol extract, through test, optimize best alcohol extraction process.See Table 5, table 6.
Preferred (the extracting 2 times) of table 5 concentration of alcohol
| Sequence number | Concentration of alcohol | Cinnamic aldehyde content (g) | Paeonol content (g) |
| 1 | 70％ | 0.24 | 0.72 |
| 2 | 80％ | 0.41 | 1.24 |
| 3 | 90％ | 0.62 | 1.80 |
Preferred (concentration of alcohol is 90%) of table 6 extraction time
| Sequence number | Extraction time | Cinnamic aldehyde content (g) | Paeonol content (g) |
| 1 | 1 time | 0.18 | 0.65 |
| 2 | 2 times | 0.67 | 1.78 |
| 3 | 3 times | 0.70 | 1.81 |
(annotate: paeonol content is 1.5% in the Cortex Moutan crude drug, and cinnamic aldehyde content is 0.5% in the Ramulus Cinnamomi.)
As shown in Table 5, in the concentration of alcohol factor of choosing, concentration be in " 90% ethanol " its extract cinnamic aldehyde and paeonol for the highest; In the table 6, extraction time is bigger to effective ingredient influence, but for the second time with compare for the third time, it is less that effective ingredient differs, basic zero difference is considered real cost of production, preferred extraction time is " 2 times ".By single factor experiment method, comprehensive content of effective optimizes the alcohol extraction optimised process and is " four Chinese medicine materials such as remaining Poria and Ramulus Cinnamomi are ground into coarse powder, and mixing adds 90% ethanol extraction 2 times ".
2 extraction process by water are preferred
Contain aqueous soluble active constituents such as effective ingredient peoniflorin in the Radix Paeoniae Alba.According to the character of water soluble ingredient, consider the cost of actual production, we extract solvent, are the investigation factor with the extraction time, are performance assessment criteria with paeoniflorin content in the water extract, show that through single factor experiment the extracting in water number of times is " 2 times ".See Table 7.
Table 7 extraction time preferred
| Sequence number | Extraction time | Content of paeoniflorin (g) |
| 1 | 1 time | 0.96 |
| 2 | 2 times | 2.56 |
| 3 | 3 times | 2.60 |
(annotate: paeoniflorin content is 2.0% in the Radix Paeoniae Alba crude drug)
As shown in Table 7, content of paeoniflorin increases along with increasing of extraction time in the extract, differs not remarkable but extract 3 times and extract 2 content of paeoniflorin, in order to adapt to the demand of actual production, saves production cost, and the preferred water extraction time is " 2 times ".
The research of experimental example 5 GUIZHI FULING JIAONANG antiinflammatory actions
1 GUIZHI FULING JIAONANG is to the bullate influence of rat granuloma
Be subjected to the reagent thing: title: GUIZHI FULING JIAONANG
The unit of providing: Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov
Preparation, lot number: the cassia twig tuckahoe extract powder is chocolate brown powder. every gram medicated powder is equivalent to crude drug 3.87g. lot number: 020420.
Compound method: facing the time spent is mixed with the concentration of 5.6% (being equivalent to crude drug 21.6%), 2.8% (being equivalent to crude drug 10.8%) and 1.4% (being equivalent to crude drug 5.4%) with distilled water.Hydrocortisone, Yangzhou pharmaceutical factory produces, specification 5mg/ml, lot number: 010105
Laboratory animal: select adult healthy SD male rat for use, 50, body weight 190 ± 20g is provided by University Of Suzhou's Experimental Animal Center, and laboratory animal is produced occupancy permit number: SCXK (Soviet Union) 2002-0021; Laboratory animal occupancy permit number: SYXK (Soviet Union) 2002-0078.
Experimental technique: get 50 of healthy SD male rats, be divided into 5 groups at random, 10 every group.Be respectively: normal control group, positive controls (with hydrocortisone intramuscular injection 5mg/kg) and the heavy dose of group of GUIZHI FULING JIAONANG (0.56gkg
-1, be equivalent to crude drug 2.16gkg
-1); Dosage group (0.28gkg in the GUIZHI FULING JIAONANG
-1, be equivalent to crude drug 1.08gkg
-1); GUIZHI FULING JIAONANG small dose group (0.14gkg
-1, be equivalent to crude drug 0.54gkg
-1).The test rat is under 4% chloral hydrate light anaesthesia, and the sterile working implants the subcutaneous stitching then of rat both sides axillary fossa with two aseptic rayon balls (weight 10 ± 1mg, diameter 6.5-8.5mm, autoclaving).Postoperative administration on the same day, once a day, hydrocortisone intramuscular injection 0.1ml/100g body weight, GUIZHI FULING JIAONANG group are irritated stomach 1ml/100g body weight, and successive administration is after 7 days, and animal is put to death in dislocation in the 8th day, takes out cotton balls, puts and weighs after 60 ℃ of baking boxs are dried.Deduct the raw cotton ball weight, be granuloma weight.Respectively organize granuloma weight and calculate suppression ratio.The formula that calculates suppression ratio is as follows:
Experimental result: the rat administration is after 7 days, and three dosage groups of GUIZHI FULING JIAONANG all have in various degree inhibitory action to connective tissue proliferation.Suppression ratio is respectively 26.48%, 19.47%, 20.25%, especially with the effect of heavy dose group the most obvious (p＜0.05).Compare with matched group, the inhibitory action of heavy dose of group is (p＜0.05) the most obviously.GUIZHI FULING JIAONANG is implanted the connective tissue proliferation that causes in the rat body to cotton balls certain inhibitory action, illustrates that GUIZHI FULING JIAONANG has the effect of antagonism proliferative inflammation., the results are shown in Table 8.
Table 8 various dose GUIZHI FULING JIAONANG is to the bullate influence of rat granuloma (x ± SD)
| Group | Dosage | Number of animals (only) | Granuloma weight (mg) | Suppression ratio (%) |
| Normal control group hydrocortisone GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG | 5mg·kg -1 0.54g·kg -1 1.08g·kg -1 2.16g·kg -1 | 10 10 10 10 10 | 64.2±21.5 42.3±1.0** 51.2±16.5 51.7±8.4 47.2±9.8* | 34.11 20.25 19.47 26.48 |
Compare * p＜0.05 with the normal control group; * p＜0.01
2 GUIZHI FULING JIAONANG are to the influence of mice auricle swelling
Be subjected to the reagent thing: title: GUIZHI FULING JIAONANG
The unit of providing: Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov
Preparation, lot number: the cassia twig tuckahoe extract powder is chocolate brown powder.Every gram medicated powder is equivalent to crude drug 3.87g.Lot number: 020420.
Compound method: facing the time spent is mixed with the concentration of 5.6% (being equivalent to crude drug 21.6%) 2.8% (being equivalent to crude drug 10.8%) and 1.4% (being equivalent to crude drug 5.4%) with distilled water.Hydrocortisone, Yangzhou pharmaceutical factory produces, specification 5mg/ml, lot number: 010105; Dimethylbenzene: Suzhou Jin Cheng chemical reagent work, lot number: 010110;
Laboratory animal: select 50 of adult healthy Kunming mouses for use, male, 23.22 ± 2.31g is provided by University Of Suzhou's Experimental Animal Center, and laboratory animal is produced occupancy permit number: SCXK (Soviet Union) 2002-0021; Laboratory animal occupancy permit number: SYXK (Soviet Union) 2002-0078.
Experimental technique: experiment is divided into 5 groups, 10 every group, is respectively 10 (1.12gkg of the heavy dose of group of normal control group, positive controls (hydrocortisone intramuscular injection 10mg/kg) and GUIZHI FULING JIAONANG
-1, be equivalent to crude drug 4.32gkg
-1); 10 (0.56gkg of dosage group in the GUIZHI FULING JIAONANG
-1, be equivalent to crude drug 2.16gkg
-1); 10 (0.28gkg of GUIZHI FULING JIAONANG small dose group
-1, be equivalent to crude drug 1.08gkg
-1).Mice gavages respectively and is subjected to reagent liquid 0.2ml/10g body weight, hydrocortisone intramuscular injection 0.02ml/10g body weight, normal control group to give isopyknic distilled water filling stomach, and administration was given proinflammatory agent after 30 minutes, and 0.03ml is applied to mouse right ear with dimethylbenzene, and left ear in contrast.2.5 after hour the dislocation of mice cervical vertebra is caused death, cut left and right ear along the auricle baseline, take off same position auricle respectively with diameter 9mm card punch, scales/electronic balance weighing, every Mus auris dextra sheet weight deducts left auricle weight, is the ear swelling degree, carries out statistical disposition.
Experimental result: 1.08,2.16 and 4.32gk
G-1The GUIZHI FULING JIAONANG of three dosage has in various degree inhibitory action to the ear swelling of mice.Along with the increase of dosage, inhibitory action progressively strengthens, and the GUIZHI FULING JIAONANG inhibitory action of especially middle heavy dose of group is (p＜0.05 the most obviously; P＜0.01).The result shows that the swelling that the GUIZHI FULING JIAONANG xylol of three dosage causes has inhibitory action, and certain dose-dependent effect is arranged.See Table 9.
The GUIZHI FULING JIAONANG of table 9 various dose is to the influence of mice ear (x ± SD)
| Group | Dosage | Number of animals (only) | Swelling degree (mg) |
| Normal control group hydrocortisone GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG | 10mg·kg -1 1.08g·kg -1 2.16g·kg -1 4.32g·kg -1 | 10 10 10 10 10 | 18.6±3.89 11.2±4.47** 15.6±5.27 14.3±3.92* 14.1±2.81** |
Compare * p＜0.05 with the normal control group; * p＜0.01,
Experimental example 6 GUIZHI FULING JIAONANG are to the influence of hemorheology of rat
Be subjected to the reagent thing: title: GUIZHI FULING JIAONANG
The unit of providing: Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov
Preparation, lot number: the cassia twig tuckahoe extract powder is chocolate brown powder. every gram medicated powder is equivalent to crude drug 3.87g.Lot number: 020420.
Compound method: facing the time spent is mixed with the concentration of 5.6% (being equivalent to crude drug 21.6%), 2.8% (being equivalent to crude drug 10.8%) and 1.4% (being equivalent to crude drug 5.4%) with distilled water.
Positive drug: QIANLIEKANG PIAN, Zhejiang Kang Enbei pharmaceutical Co. Ltd product, lot number: 020115; Facing the time spent is mixed with 17% concentration with distilled water.
Androlin, Shanghai the 9th pharmaceutical factory produces, specification: 25mg/ml. lot number: 020506; Facing the time spent is diluted to 10mg/ml concentration with olive oil.
Laboratory animal and material: male SD rat, 60, body weight 237.9 ± 30.1 gram is provided by University Of Suzhou's Experimental Animal Center, and laboratory animal is produced occupancy permit number: SCXK (Soviet Union) 2002-0021; Laboratory animal occupancy permit number: SYXK (Soviet Union) 2002-0078.
The hemorheology instrument: Beijing Puli gives birth to centre; Model: LBY-N6
Experimental technique: select 60 of healthy male SD rat for use, take out 10 at random as normal group.Use 4% chloral hydrate anesthesia for 50 in addition, under aseptic condition, extract bilateral testes, then skin suture.After one week, castrated rats is divided into 5 groups at random, 10 every group, is respectively model group; The heavy dose of group of GUIZHI FULING JIAONANG (0.56gkg
-1, be equivalent to crude drug 2.16gkg
-1); Dosage group (0.28gkg in the GUIZHI FULING JIAONANG
-1, be equivalent to crude drug 1.08gkg
-1); GUIZHI FULING JIAONANG small dose group (0.14gkg
-1, be equivalent to crude drug 0.54gkg
-1); Positive drug control group (QIANLIEKANG 1.7gkg
-1); The laboratory animal sub-cage rearing, except that normal group, all the other rat sc every day androlins (1mg/300g body weight) once, the medication group is gavaged medicinal liquid 1ml/100g body weight simultaneously, normal group gives equal-volume water and irritates stomach.Rat is weighed once weekly, and adjusts dosage.Postoperative played successive administration on the 7th 30.4% chloral hydrate (400mg/kg) anesthesia after the last administration, rat aorta is got blood 4.0ml, injects the anticoagulant tube that heparin is handled, and measures the hemorheology of rat index through the rotary hemorheology instrument of LBY-N6 type.
Experimental result: administration group and model group compare, and whole blood viscosity, whole blood reduced viscosity have than significant difference.The big or middle dosage group of GUIZHI FULING JIAONANG is compared with model group and can significantly be reduced rat blood viscosity (P＜0.05; P＜0.01).GUIZHI FULING JIAONANG administration group can reduce that the reduction of rat whole blood, whole blood is low cuts, in cut viscosity, compare difference highly significant (P＜0.05 with model group; P＜0.01).See Table 10.
Table 10 GUIZHI FULING JIAONANG to the influence of prostatic hyperplasia hemorheology of rat (x ± SD, n=10)
| Group | Dosage (crude drug gkg -1) | Whole blood viscosity/mpas | Whole blood reduced viscosity/mpas | ||||
| Low cutting | In cut | Height is cut | Low cutting | In cut | Height is cut | ||
| Normal group model group GUIZHI FULING JIAONANG Ramulus Cinnamomi Indian buead capsule GUIZHI FULING JIAONANG QIANLIEKANG PIAN group | 2.16 1.08 0.54 1.7 | 7.852±0.817 10.972±1.284 9.730±0.989* 9.562±1.341* 11.563±1.894 11.308±1.605 | 4.682±0.321 5.763±0.343 5.436±0.334* 5.063±0.790* 5.841±0.602 5.895±0.483 | 4.002±0.267 4.776±0.240 4.559±0.280 4.232±0.764* 4.780±0.519 4.893±0.425 | 16.094±2.315 20.829±3.059 18.299±2.271 17.229±2.268** 20.954±3.666 20.819±3.048 | 8.097±1.181 9.33±0.650 8.542±0.978* 7.480±1.397** 8.769±0.976 9.315±0.950 | 6.355±1.087 7.156±0.433 6.539±0.835 5.656±1.346** 6.511±0.980 7.173±0.844 |
Compare * P＜0.05 with model group; * P＜0.01
Experimental example 7 GUIZHI FULING JIAONANG cause the effect of rat mammary gland model of hyperplasia to estrogen
Be subjected to the reagent thing: breast rather increases: get breast and increase 32, be settled to 100ml with water dissolution; GUIZHI FULING JIAONANG heavy dose: get GUIZHI FULING JIAONANG powder 29.7g, be settled to 100ml with water dissolution; Dosage in the GUIZHI FULING JIAONANG: get GUIZHI FULING JIAONANG powder 9.9g, be settled to 100ml with water dissolution; GUIZHI FULING JIAONANG low dose: get GUIZHI FULING JIAONANG powder 3.3g, be settled to 100ml with water dissolution.
Experimental animal: 72 female unpregnancy healthy SD rats, body weight 180 ± 10g is provided by Nanjing University of Traditional Chinese Medicine's Experimental Animal Center.Kinoplaszm: SCXK (Soviet Union) 2002-0012 of Soviet Union.
Experimental technique: Healthy female is 72 of pregnant rats not, be divided into 6 groups at random, normal control group (12), model group (11), breast increases peaceful group of (1.92g/kg, 11), the heavy dose of group of GUIZHI FULING JIAONANG (11.5g crude drug/kg, 11), middle dosage group (3.83g crude drug/kg, 12), small dose group (1.28g crude drug/kg, 11), except that the normal control group, all the other are respectively organized rat and alternately injected estradiol benzoate 0.6mg/kg every 1 day in preceding oxter, inject altogether 10 times, irritate stomach simultaneously respectively and give each relative medicine (normal control group and model group are irritated the isopyknic tap water of stomach), the normal control group is next day injection and the isopyknic physiological saline solution of estradiol benzoate then, and after the last administration 24 hours, the ball posterior vein was got blood, separation of serum is measured E2 in the serum, P, T, PRL level (RIA method); Get the mammary gland of the 3rd pair of breast, carry out embedding, section, HE dyeing, mirror is observed its morphological changes of various tissue components down, and gets uterus and ovary, thymus and spleen, weighs and calculates its organ coefficient, and mirror is observed its morphological changes of various tissue components down.
Experimental result
The pathological grading of 1 pair of mammary gland tissue influence and mirror are observed down
The mammary gland pathological grading: the I level: lobules of mammary gland is obvious, and volume increases, and acinus quantity increases in the lobule, and conduit is extremely expanded, and in the lumen of gland or in the conduit volume secretions is arranged; The II level: lobules of mammary gland is obvious, and volume increases, but it is obvious not have the I level, in tube chamber or the ductal ectasia, lumen of gland or in the conduit secretions is arranged; The III level: the part cyclomastopathy, volume increases, and lumen of gland or conduit are slightly expanded, and in the lumen of gland or in the conduit a small amount of secretions are arranged; IV level (normal galactophore tissue): lobules of mammary gland is hypertrophy not, and the acinus volume is normal, and lumen of gland and conduit are not expanded, and does not see obvious secretions in lumen of gland and the conduit.Om observation the results are shown in Table 11.
Table 11 GUIZHI FULING JIAONANG is to the influence of cyclomastopathy Rats Organs and Tissues coefficient
| Group | Number of animals n | The I level | The II level | The III level | The IV level | 95% confidence interval |
| Normal group model group breast increases dosage group small dose group in peaceful group of heavy dose of group | 12 11 11 11 12 11 | 0 10 8 6 7 8 | 0 1 3 3 4 2 | 0 0 0 2 1 1 | 12 0 0 0 0 0 | 0.912±0.014 0.322±0.015 ** 0.391±0.015 ## 0.483±0.015 ## 0.456±0.014 ## 0.402±0.015 ## |
Annotate: compare #P＜0.05 ##P＜0.01 with model group
Compare * P＜0.05 * * P＜0.01 with normal group
By table 1 as seen, relatively there were significant differences for normal group and model group, and each treatment group and model group also have significant difference.
The influence of 2 pairs of cyclomastopathy Rats Organs and Tissues coefficients
Table 12 GUIZHI FULING JIAONANG is to the influence of cyclomastopathy Rats Organs and Tissues coefficient
| Group | Body weight (g) | Thymus coefficient (mg/g) | Uterus ovary coefficient (mg/g) | Spleen coefficient (mg/g) |
| Normal group model group breast increases dosage group small dose group in peaceful group of heavy dose of group | 238.7±26.0 211.9±20.6 200.8±27.2 237.3±32.4 215.1±16.8 210.4±33.1 | 2.24±0.47 1.63±0.56 ** 1.33±0.18 1.48±0.48 1.61±0.37 1.55±0.34 | 2.42±0.78 4.30±1.41 ** 4.12±1.08 3.64±1.12 4.35±1.23 4.31±1.22 | 5.95±1.61 6.28±1.01 5.84±1.95 5.14±1.57 5.35±1.18 5.20±2.10 |
Annotate: compare #P＜0.05 ##P＜0.01 with model group
Compare * P＜0.05 * * P＜0.01 with normal group
By table 12 as seen, normal group and model group compare the uterus coefficient, there were significant differences for the thymus coefficient, wherein the thymus coefficient of model group obviously reduces, and uterus ovary coefficient and the apparent in view increase of model group, GUIZHI FULING JIAONANG heavy dose, middle dosage and breast increase peaceful group and organ coefficient does not have significant difference.
The influence of 3 pairs of cyclomastopathy rat sex hormone levels
Table 13 GUIZHI FULING JIAONANG is to the influence of gonadal hormone in the cyclomastopathy rat blood serum
| Group | E 2(pg/ml) | T(pg/ml) | P(pg/ml) | PRL(pg/ml) |
| Normal group model group breast increases dosage group small dose group in peaceful group of heavy dose of group | 97.55±127.37 749.05±100.92 ** 825.30±136.66 844.90±113.24 734.33±109.99 819.08±144.47 | 17.73±15.93 16.70±15.61 9.50±5.87 12.30±11.39 24.57±20.39 11.90±14.82 | 11.76±6.95 14.62±11.40 22.09±11.03 27.36±5.12 ## 22.86±12.86 19.83±10.34 | 0.87±0.38 0.87±0.42 1.27±0.36 ## 1.16±0.66 1.81±1.19 ## 1.96±1.40 ## |
Annotate: compare #P＜0.05 ##P＜0.01 with model group
Compare * P＜0.05 * * P＜0.01 with normal group
By table 13 as seen, model group serum E
2Level is significantly higher than the normal control group, the cassia twig tuckahoe glue heavy dose P that can raise, and relatively there were significant differences with model group; Breast increases in peaceful group and the cassia twig tuckahoe glue, low dose can raise PRL, and with model group significant difference is arranged relatively.
Experimental example 8 GUIZHI FULING JIAONANG are to the experimentation of treatment rat experiment prostatic hyperplasia pathological model
Be subjected to the reagent thing: title: GUIZHI FULING JIAONANG
The unit of providing: Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov
Preparation, lot number: the cassia twig tuckahoe extract powder is chocolate brown powder. every gram medicated powder is equivalent to crude drug 3.87g. lot number: 020420.
Compound method: facing the time spent is mixed with the concentration of 5.6% (being equivalent to crude drug 21.6%), 2.8% (being equivalent to crude drug 10.8%) and 1.4% (being equivalent to crude drug 5.4%) with distilled water.
Positive drug: QIANLIEKANG PIAN, Zhejiang Kang Enbei pharmaceutical Co. Ltd product, lot number: 020115; Facing the time spent is mixed with 17% concentration with distilled water.
Androlin: Shanghai the 9th pharmaceutical factory produces, specification: 25mg/ml. lot number: 020506; Facing the time spent is diluted to 10mg/ml concentration with olive oil.
Laboratory animal: the SD rat, male, 60, body weight 237.9 ± 30.1 is provided by University Of Suzhou's Experimental Animal Center.Laboratory animal is produced occupancy permit number: SCXK (Soviet Union) 2002-0021; Laboratory animal occupancy permit number: SYXK (Soviet Union) 2002-0078.
Experimental technique: select 60 of healthy male SD rat for use, take out 10 at random as normal group.Use 4% chloral hydrate anesthesia for 50 in addition, under aseptic condition, extract bilateral testes, then skin suture.After one week, castrated rats is divided into 5 groups at random, 10 every group, is respectively model group; The heavy dose of group of GUIZHI FULING JIAONANG (0.56gkg
-1, be equivalent to crude drug 2.16gkg
-1); Dosage group (0.28gkg in the GUIZHI FULING JIAONANG
-1, be equivalent to crude drug 1.08gkg
-1); GUIZHI FULING JIAONANG small dose group (0.14gkg
-1, be equivalent to crude drug 0.54gkg
-1); Positive drug control group (QIANLIEKANG 1.7gkg
-1); The laboratory animal sub-cage rearing, except that normal group, all the other rat sc every day androlins (1mg/300g body weight) once, the medication group is gavaged medicinal liquid 1ml/100g body weight simultaneously, normal group gives equal-volume water and irritates stomach.Rat is weighed once weekly, and adjusts dosage.Postoperative played successive administration on the 7th 30.1h puts to death animal after the last administration, gets each leaf of prostate, and electronic balance claims weight in wet base, and volumetric method is surveyed prostate volume, gets left and right sides head lobe and claims weight in wet base and claim dry weight after 37 ℃ of oven dry, calculated weight coefficient (being the weight of prostate or the volume of every 100g rat body weight).Getting the siphonal lobe prostate is fixed in and does routine paraffin wax section in 10% formalin solution, the HE microscopy.
Experimental result
1, GUIZHI FULING JIAONANG is to rat prostate weight, the influence of volume
Each dosage group of GUIZHI FULING JIAONANG is compared with model group, can obviously alleviate the rat prostate head lobe and do weight in wet base, alleviates the siphonal lobe weight in wet base, reduces prostate volume.Especially the most obvious with the big or middle dosage group of GUIZHI FULING JIAONANG effect, compare difference highly significant (P＜0.01) with model group.See Table 14,15.
Table 14 GUIZHI FULING JIAONANG to the outgrowth influence of rat experiment prostate head lobe (x ± SD, n=10)
| Group | Dosage (g/kg) | Head lobe (weight in wet base) left side | (mg/100g body weight) right side | Head lobe (dry weight) left side | (mg/100g body weight) right side |
| Normal group model group GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG positive drug group | 2.16 1.08 0.54 1.7 | 20.61±5.41 69.34±13.86 47.22±8.76** 51.04±8.13** 49.97±11.46** 45.58±8.10** | 24.76±6.43 70.20±11.98 48.77±12.50** 54.15±6.90** 50.59±12.06** 46.96±8.23** | 3.92±0.86 13.0±2.60 9.27±2.44** 9.83±1.63** 9.29±1.50** 9.13±2.25** | 4.76±1.58 12.58±3.23 9.31±2.01* 9.69±1.55* 9.58±1.74* 9.35±1.96* |
Compare * P＜0.05 with model group; * P＜0.01
Table 15 GUIZHI FULING JIAONANG to the influence of rat prostate siphonal lobe and volume (x ± SD, n=10)
| Group | Dosage (g/kg) | Siphonal lobe (weight in wet base) (mg/100g body weight) | Volume (cm 3/ 100g body weight) |
| Normal group model group GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG | 2.16 1.08 0.54 | 111.18±26.91 270.11±49.03 170.40±42.10** 204.02±34.70** 265.49±84.80 | 0.132±0.017 0.349±0.058 0.187±0.093** 0.262±0.040** 0.307±0.087 |
Compare * P＜0.05 with model group; * P＜0.01
2, pathology microscopy result: normal group prostate body of gland marshalling, lumen of gland does not have expansion, glandular epithelium is the monolayer column, between body of gland visible between matter.Model group shows the body of gland arrangement closely, and the epithelial cell number increases, and is high column more, and the glandular epithelium height increases, and forms mamillary and charges in the lumen of gland, and lumen of gland is obviously expanded, interior visible secretions.GUIZHI FULING JIAONANG small dose group body of gland is arranged slightly tight, visible papillary hyperplasia in the lumen of gland.The heavy dose of group of GUIZHI FULING JIAONANG, middle dosage group pathological examination shows, the lumen of gland expansion is not obvious, hypertrophy glandular epithelium number obviously is less than model group, and low columnar epithelium is seen more, it is normal that part is tending towards recovering, and the lumen of gland diameter is compared with model group with the glandular epithelium height, difference highly significant (P＜0.05; P＜0.01).See Table 16.
Table 16 GUIZHI FULING JIAONANG is to the influence of rat prostate lumen of gland diameter and glandular epithelium height (x ± SD)
| Group | Dosage (g/kg) | Number of animals (only) | Lumen of gland diameter (μ m) | Glandular epithelium height (μ m) |
| Normal group model group GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG positive drug group | 2.16 1.08 0.54 1.7 | 10 10 10 10 10 10 | 171.0±34.14 287.0±51.43 231.0±41.22* 243.0±34.98* 254.0±39.21 239.0±32.81* | 16.9±2.23 27.3±3.65 21.3±3.27** 23.0±4.06* 24.9±4.84 22.5±4.35* |
Compare * P＜0.05 with model group; * P＜0.01
Experimental example 9 GUIZHI FULING JIAONANG are to the influence of the mouse retention gential sinus property implanted prostatic hyperplasia model
Be subjected to the reagent thing: title: GUIZHI FULING JIAONANG
The unit of providing: Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov
Preparation, lot number: the cassia twig tuckahoe extract powder is chocolate brown powder. every gram medicated powder is equivalent to crude drug 3.87g. lot number: 020420.
Compound method: facing the time spent is mixed with the concentration of 5.6% (being equivalent to crude drug 21.6%), 2.8% (being equivalent to crude drug 10.8%) and 1.4% (being equivalent to crude drug 5.4%) with distilled water.
Positive drug: QIANLIEKANG PIAN, Zhejiang Kang Enbei pharmaceutical Co. Ltd product, lot number: 020115; Facing the time spent is mixed with 17% concentration with distilled water.
Laboratory animal: select 60 of adult healthy Kunming mouses for use, male, 25.41 ± 3.16g is provided by University Of Suzhou's Experimental Animal Center, and laboratory animal is produced occupancy permit number: SCXK (Soviet Union) 2002-0021; Laboratory animal occupancy permit number: SYXK (Soviet Union) 2002-0078.
Experimental technique: select 60 of male mices for use, lumbar injection pentobarbital sodium anesthesia (3%, 60mg/kg), abdomen center, aseptic condition lower edge is cut stomach wall open, separate the prostate siphonal lobe gently with tweezers, the urogenital sinus tissue of implantation tire Mus in 3 16 day ages is sewed up abdominal wall muscle, skin under anatomical lens, mouse cage is put back in sterilization.Divide into groups then, 10 of normal group gavage the equal-volume normal saline, 10 of model group, 10 (1.12gkg of the heavy dose of group of GUIZHI FULING JIAONANG
-1, be equivalent to crude drug 4.32gkg
-1); 10 (0.56gkg of dosage group in the GUIZHI FULING JIAONANG
-1, be equivalent to crude drug 2.16gkg
-1); 10 (0.28gkg of GUIZHI FULING JIAONANG small dose group
-1, be equivalent to crude drug 1.08gkg
-1); 10 (3.4gkg of QIANLIEKANG group
-1).The free diet of all mices, in postoperative beginning in the 3rd day gastric infusion, administration volume 0.2ml/10g body weight, once a day, successive administration is after 30 days, and disconnected marrow is put to death mice, gets each leaf of prostate respectively, and testis and seminal vesicle claim weight in wet base with electronic balance.Get a side head lobe and claim weight in wet base and claim dry weight after 37 ℃ of oven dry, calculated weight coefficient (being the body of gland weight of every gram mice body weight) is got prostate siphonal lobe fixation of tissue in addition in 10% formalin solution, send the section microscopy.
Experimental result
1, GUIZHI FULING JIAONANG is to the influence of mice weight of prostate
Each dosage group of GUIZHI FULING JIAONANG is compared with model group, can obviously alleviate mice prostate head lobe and do weight in wet base, alleviate siphonal lobe weight in wet base and weight of seminal vesicle, the most obvious with the big or middle dosage group of GUIZHI FULING JIAONANG effect especially, compare significant difference (P＜0.05 with model group; P＜0.01).See Table 17.
Table 17 GUIZHI FULING JIAONANG to the influence of mouse experiment prostatic hyperplasia (x ± SD, n=10)
| Group | Dosage (g/kg) | Head lobe | Siphonal lobe weight in wet base (mg/g) | Seminal vesicle (mg/g) | Testis (mg/g) | |
| Weight in wet base (mg/g) | Dry weight (mg/g) | |||||
| Normal group model group GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG positive drug group | 4.32 2.16 1.08 3.4 | 0.780±0.103 1.298±0.377 0.844±0.095 ** 0.935±0.147 * 0.937±0.175 * 0.871±0.136 ** | 0.186±0.055 0.304±0.110 0.166±0.027 ** 0.196±0.053 * 0.222±0.074 0.188±0.043 ** | 0.395±0.14 0.676±0.162 0.473±0.123 ** 0.478±0.168 * 0.516±0.095 * 0.489±0.157 * | 3.737±1.02 5.817±0.726 4.181±0.908 ** 4.416±0.857 ** 4.771±0.811 ** 4.040±0.728 ** | 6.203±1.036 4.308±1.217 5.168±1.044 5.383±1.407 5.289±1.062 6.247±0.644 ** |
Compare * P＜0.05 with model group; * P＜0.01
2, the pathology microscopy is found
Normal group prostate body of gland marshalling, glandular epithelium is the monolayer column, lumen of gland does not have expansion, between body of gland visible between matter.Model group shows glandular hyperplasia, arranges closely, and companion's stroma hypertrophy, the lumen of gland expansion, the epithelial cell number that is high column increases, and forms mamillary and charges in the lumen of gland.The heavy dose of group of GUIZHI FULING JIAONANG, middle dosage arrangement of mirrors inspection section result shows: the lumen of gland expansion is lighter; Glandular epithelium height, lumen of gland diameter are significantly less than model group, significant difference (P＜0.05); Hypertrophy glandular epithelium number obviously is less than model group, and low columnar epithelium is seen more; The small dose group effect is not too obvious, visible more basal cell, and a matter is more.The experimental result prompting: GUIZHI FULING JIAONANG can effectively be treated the mice prostatic hyperplasia.See Table 18
Table 18 GUIZHI FULING JIAONANG is to the influence of mice prostate lumen of gland diameter and glandular epithelium height (x ± SD)
| Group | Dosage (gkg -1) | Number of animals (only) | Lumen of gland diameter (μ m) | Glandular epithelium height (μ m) |
| Normal group model group GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG GUIZHI FULING JIAONANG positive drug group | 4.32 2.16 1.08 3.4 | 10 10 10 10 10 10 | 96.7±33.47 152.0±20.44 127.8±22.10* 131.5±19.44* 139.0±25.14 118.0±30.48* | 11.5±2.99 17.1±4.15 13.2±3.16* 13.6±2.80* 15.0±2.87 12.8±3.08* |
Compare * P＜0.05 with model group
The technology of embodiment 1 preparation Cinnamomi and poria composition
1 raw material is formed: Ramulus Cinnamomi 240g, Poria 240g, Cortex Moutan 240g, Radix Paeoniae Alba 240g, Semen Persicae 240g.Make 1000.
2 preparation technologies: the extraction process of Cortex Moutan should be medical material and breaks into coarse powder and cross 10 mesh sieves, add water-wet after 1.5 hours,, collect 5 times of amount distillates with circulation steam distillation, cold preservation is left standstill, after waiting to separate out crystallization, filter, filtrate is redistillation again, collect 3 times of amount distillates, cold preservation is left standstill, and filters after waiting to separate out crystallization, merges twice crystallization by being proposed the paeonol crystallization.Be ground into fine powder after drying in the shade, make fine grained, dry in the shade, the cryogenic seal storage, stand-by; The Poria powder of Ramulus Cinnamomi, the Radix Paeoniae Alba, Semen Persicae and recipe quantity 20% is broken into coarse powder, mixing; Add the Cortex Moutan medicinal residues, add 90% ethanol of 4 times of amounts of medical material again, soaked 30 minutes, heating and refluxing extraction 2 hours filters, and medicinal residues add 90% ethanol of 3 times of amounts of crude drug again, and reflux, extract, 2 hours filters; Merging filtrate.Medicinal residues add the water of 6 times of amounts of crude drug, and reflux, extract, 1 hour filters; Medicinal residues add the water of 4 times of amounts of crude drug again, and reflux, extract, 1 hour filters, merging filtrate, and medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor.Merge two concentrated solutions, get sepia thickness mastic, relative density is 1.25 (80 ℃); With the Poria fine powder (100 order) and above-mentioned extractum mixing of other 80% recipe quantity, drying is pulverized, and granulates oven dry; Add the paeonol fine grained, mixing is crossed 20 mesh sieves, promptly.
The technology of embodiment 2 preparation GUIZHI FULING JIAONANG
1 raw material is formed: Ramulus Cinnamomi 240g, Poria 240g, Cortex Moutan 240g, Radix Paeoniae Alba 240g, Semen Persicae 240g.Make 1000.
2 preparation technologies: the extraction process of Cortex Moutan should be medical material and breaks into coarse powder and cross 10 mesh sieves, add water-wet after 1.5 hours,, collect 9 times of amount distillates with circulation steam distillation, cold preservation is left standstill, after waiting to separate out crystallization, filter, filtrate is redistillation again, collect 3 times of amount distillates, cold preservation is left standstill, and filters after waiting to separate out crystallization, merges twice crystallization by being proposed the paeonol crystallization.Be ground into fine powder after drying in the shade, make fine grained, dry in the shade, the cryogenic seal storage, stand-by; The Poria powder of Ramulus Cinnamomi, the Radix Paeoniae Alba, Semen Persicae and recipe quantity 20% is broken into coarse powder, mixing; Add the Cortex Moutan medicinal residues, add 90% ethanol of 4 times of amounts of medical material again, soaked 30 minutes, heating and refluxing extraction 2 hours filters, and medicinal residues add 90% ethanol of 3 times of amounts of crude drug again, and reflux, extract, 2 hours filters; Merging filtrate.Medicinal residues add the water of 6 times of amounts of crude drug, and reflux, extract, 1 hour filters; Medicinal residues add the water of 4 times of amounts of crude drug again, and reflux, extract, 1 hour filters, merging filtrate, and medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor.Merge two concentrated solutions, get sepia thickness mastic, relative density is 1.25 (80 ℃); With the Poria fine powder (100 order) and above-mentioned extractum mixing of other 80% recipe quantity, drying is pulverized, and granulates oven dry; Add the paeonol fine grained, mixing is crossed 20 mesh sieves, in incapsulating, makes 1000, promptly.Every heavy 0.31g is equivalent to crude drug 1.20g.
The technology of embodiment 3 preparation GUIZHI FULING JIAONANG
1 raw material is formed: Ramulus Cinnamomi 240g, Poria 240g, Cortex Moutan 240g, Radix Paeoniae Alba 240g, Semen Persicae 240g.Make 1000.
2 preparation technologies: the Poria five kinds of Chinese medicine of getting Ramulus Cinnamomi, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan and 50% recipe quantity is broken into coarse powder, and mixing adds 90% ethanol of 3 times of amounts of medical material, soaks 0.5 hour, and heating and refluxing extraction 1 hour filters; Medicinal residues add 90% ethanol of 3 times of amounts of crude drug again, and reflux, extract, filters merging filtrate; Medicinal residues add the water of 5 times of amounts of crude drug, and reflux, extract, 0.5 hour filters; Medicinal residues add the water of 5 times of amounts of crude drug, and reflux, extract, 0.5 hour filters; Merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia extractum; With the Poria fine powder and the above-mentioned extractum mixing of other 50% recipe quantity, drying is pulverized, and granulates, and 20 mesh sieves are crossed in oven dry, in incapsulating, make 1000, promptly.Every heavy 0.31g is equivalent to crude drug 1.20g.
The technology of embodiment 4 preparation cassia twig tuckahoe tablets
1 raw material is formed: Ramulus Cinnamomi 240g, Poria 240g, Cortex Moutan 240g, Radix Paeoniae Alba 240g, Semen Persicae 240g.Make 1000.
2 preparation technologies: the Poria five kinds of Chinese medicine of getting Ramulus Cinnamomi, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan and 50% recipe quantity is broken into coarse powder, and mixing adds 90% ethanol of 3 times of amounts of medical material, soaks 0.5 hour, and heating and refluxing extraction 1 hour filters; Medicinal residues add 90% ethanol of 3 times of amounts of crude drug again, and reflux, extract, filters merging filtrate; Get cinnamic aldehyde content 0.67g, paeonol content 1.78g; Medicinal residues add the water of 5 times of amounts of crude drug, and reflux, extract, 0.5 hour filters; Medicinal residues add the water of 5 times of amounts of crude drug, and reflux, extract, 0.5 hour filters; Content of paeoniflorin 2.56g, merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia extractum; With the Poria fine powder and the above-mentioned extractum mixing of other 50% recipe quantity, drying is pulverized, granulate, and oven dry, through the pelletizing machine granulate, tabletting, every heavy 0.31g is equivalent to crude drug 1.20g.
The application of embodiment 5 Cinnamomi and poria compositions in the medicine of treatment prostatic hyperplasia
Ramulus Cinnamomi 240g, Poria 240g, Cortex Moutan 240g, Radix Paeoniae Alba 240g, Semen Persicae 240g.Make 1000,0.31g/ grain or sheet, the patient of trouble prostatoplasia diseases, oral, each 3, every day 3 times.
The application of embodiment 6 Cinnamomi and poria compositions in the medicine of treatment cyclomastopathy
Ramulus Cinnamomi 240g, Poria 240g, Cortex Moutan 240g, Radix Paeoniae Alba 240g, Semen Persicae 240g.Make 1000,0.31g/ grain or sheet, the patient of trouble hyperplasia of mammary glands, oral, each 3, every day 3 times.
Claims (5)
1, a kind of Cinnamomi and poria composition is characterized in that said composition is prepared by following method:
Get equivalent Ramulus Cinnamomi, Poria, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan five kinds of Chinese medicine; The Poria five kinds of Chinese medicine of getting Ramulus Cinnamomi, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan and 40%-60% recipe quantity is broken into coarse powder, mixing; Add 70%-90% ethanol, soaked 0.5-1 hour, heating and refluxing extraction 1-3 time wherein adds the alcoholic acid amount of 70%-90% at every turn and is 3-5 times of crude drug, and the heating and refluxing extraction time is 1-3 hour; Filter merging filtrate; Medicinal residues add the water that crude drug 5-7 doubly measures, reflux, extract, 1-3 time, wherein each reflux extracting time 0.5-1 hour; Filter, merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia extractum; With the Poria fine powder and the above-mentioned extractum mixing of other 40%-60% recipe quantity, drying is pulverized, granulate, and oven dry, granulate, promptly.
2, Cinnamomi and poria composition according to claim 1 is characterized in that said composition is prepared by following method:
Get equivalent Ramulus Cinnamomi, Poria, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan five kinds of Chinese medicine; The Poria five kinds of Chinese medicine of getting equivalent Ramulus Cinnamomi, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan and 50% recipe quantity is broken into coarse powder, mixing; Add 90% ethanol, soaked 0.5 hour, heating and refluxing extraction 2 times, the 90% alcoholic acid amount that wherein at every turn adds is 3 times of crude drug, the heating and refluxing extraction time is 1 hour; Filter merging filtrate; Medicinal residues add the water of 5 times of amounts of crude drug, reflux, extract, 2 times, wherein each reflux extracting time 0.5 hour; Filter, merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia extractum; With the Poria fine powder and the above-mentioned extractum mixing of other 50% recipe quantity, drying is pulverized, granulate, and oven dry, granulate, promptly.
3, a kind of preparation method of Cinnamomi and poria composition is characterized in that this method is:
Get equivalent Ramulus Cinnamomi, Poria, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan five kinds of Chinese medicine; The Poria five kinds of Chinese medicine of getting Ramulus Cinnamomi, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan and 40%-60% recipe quantity is broken into coarse powder, mixing; Add 70%-90% ethanol, soaked 0.5-1 hour, heating and refluxing extraction 1-3 time wherein adds the alcoholic acid amount of 70%-90% at every turn and is 3-5 times of crude drug, and the heating and refluxing extraction time is 1-3 hour; Filter merging filtrate; Medicinal residues add the water that crude drug 5-7 doubly measures, reflux, extract, 1-3 time, wherein each reflux extracting time 0.5-1 hour; Filter, merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia extractum; With the Poria fine powder and the above-mentioned extractum mixing of other 40%-60% recipe quantity, drying is pulverized, granulate, and oven dry, granulate, promptly.
4, as the preparation method of Cinnamomi and poria composition as described in the claim 3, it is characterized by and be that this method is:
Get equivalent Ramulus Cinnamomi, Poria, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan five kinds of Chinese medicine; The Poria five kinds of Chinese medicine of getting equivalent Ramulus Cinnamomi, Semen Persicae, the Radix Paeoniae Alba, Cortex Moutan and 50% recipe quantity is broken into coarse powder, mixing; Add 90% ethanol, soaked 0.5 hour, heating and refluxing extraction 2 times, the 90% alcoholic acid amount that wherein at every turn adds is 3 times of crude drug, the heating and refluxing extraction time is 1 hour; Filter merging filtrate; Medicinal residues add the water of 5 times of amounts of crude drug, reflux, extract, 2 times, wherein each reflux extracting time 0.5 hour; Filter, merging filtrate, medicinal residues are abandoned it; Alcohol extract and water extract be concentrating under reduced pressure respectively, and alcohol extract is recycled to does not have the alcohol flavor; Merge two concentrated solutions, get sepia extractum; With the Poria fine powder and the above-mentioned extractum mixing of other 50% recipe quantity, drying is pulverized, granulate, and oven dry, granulate, promptly.
5, as any one Cinnamomi and poria composition as described in the claim 1-2, it is characterized in that this Cinnamomi and poria composition makes oral formulations, its oral formulations is selected from a kind of in the middle of tablet, pill, capsule, granule, suspensoid, drop pill or the oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310116836 CN1296069C (en) | 2003-11-28 | 2003-11-28 | Preparing technics of composition of Guizhi and Fuling and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310116836 CN1296069C (en) | 2003-11-28 | 2003-11-28 | Preparing technics of composition of Guizhi and Fuling and its use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101113426A Division CN100560094C (en) | 2003-11-28 | 2003-11-28 | Preparation technology of Cinnamomi and poria composition and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1546129A CN1546129A (en) | 2004-11-17 |
| CN1296069C true CN1296069C (en) | 2007-01-24 |
Family
ID=34337634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310116836 Expired - Lifetime CN1296069C (en) | 2003-11-28 | 2003-11-28 | Preparing technics of composition of Guizhi and Fuling and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1296069C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101036709B (en) * | 2006-03-15 | 2011-02-09 | 北京因科瑞斯生物制品研究所 | Chinese medicine preparation for treating gynecopathy and its preparing process |
| CN103536738B (en) * | 2013-10-29 | 2015-04-08 | 江西天施康中药股份有限公司 | Preparation method of compound black-bone chicken preparation |
| CN104784286A (en) * | 2015-05-11 | 2015-07-22 | 李汶峰 | Traditional Chinese medicine for treating hyperplasia of mammary glands |
| CN111122728B (en) * | 2019-12-24 | 2021-03-26 | 江苏康缘药业股份有限公司 | Detection method of cassia twig and poria cocos capsules |
| CN112545941A (en) * | 2020-12-17 | 2021-03-26 | 广州环亚化妆品科技有限公司 | Traditional Chinese medicine composition with whitening, anti-inflammatory and anti-aging functions and preparation method and application thereof |
-
2003
- 2003-11-28 CN CN 200310116836 patent/CN1296069C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1546129A (en) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN1857352A (en) | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases | |
| CN1931247A (en) | Medicine for treating rhinitis and its prepn process | |
| CN1233387C (en) | Chinese compound medicine for treating anhypnosis and its preparation metod | |
| CN1323697C (en) | Combination of Chinese traditional medicine for treating deafness and tinnitus, and preparation method | |
| CN1296069C (en) | Preparing technics of composition of Guizhi and Fuling and its use | |
| CN1283291C (en) | Compound preparation for bone fracture and its preparation method | |
| CN1608662A (en) | Medicine with antiphlogistic, analgetic, microbiostatic and diuretic effects | |
| CN1238024C (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
| CN1927288A (en) | Preparing art of cassia twig and Tuckahoe composition and use thereof | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1876096A (en) | Main component of Chinese medicinal capsule for treating climacteric syndrome and preparation method thereof | |
| CN1544032A (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN1876097A (en) | Improved Chinese medicinal capsule for treating climacteric syndrome | |
| CN1771042A (en) | Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents | |
| CN1190228C (en) | Angong hemostatics | |
| CN1305487C (en) | Medicinal composition for treating dysuria due to benign prostatauxe and its preparation method | |
| CN1053376C (en) | Antineoplastic Chinese medicine prepn and its prepn process | |
| CN1660865A (en) | Saponin compound, general saponin of cynanchum bunaei and application in medication for treating disease of gstrointestinal tract | |
| CN1313085C (en) | Application of total hypone of radix cynanchi bungei and hypnone for preparing medicine for treating gastrointestinal tract diseases | |
| CN1261452C (en) | Sugar latticeing material CHB extracted from serum of turtle or/and tortoise, preparation process and application in pharmacy thereof | |
| CN1493299A (en) | Application of akebia saponin D in preparation of medicine for proventing and treating osteo pathic | |
| CN1244341C (en) | Chinese medicine composition for treating endometriosis and its prepn process | |
| CN1234403C (en) | Chinese medicine for treating gastric disease | |
| CN1583133A (en) | Effervescent tablets for bone diseases and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070124 |